NDAINJECTIONINJECTABLE1 Generic Approved
Approved
Jun 2011
Lifecycle
Peak
Competitive Pressure
45/100
Clinical Trials
20
Data completeness
3/8 — Basic
Drug data last refreshed 13h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Docetaxel is a small-molecule taxane chemotherapy agent administered by injection for the treatment of various solid tumors including breast cancer, non-small cell lung cancer, prostate cancer, and gastric cancer. It works by stabilizing microtubules and inhibiting cell division, leading to cancer cell death. The drug is a semisynthetic derivative of paclitaxel with improved efficacy and tolerability profiles.
Peak
Docetaxel is at peak lifecycle stage with moderate competitive pressure (45/100), indicating a mature, stable franchise with established market presence and a large support infrastructure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer
Started Feb 2027
393 enrolled
Bladder (Urothelial, Transitional Cell) CancerBladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)Urothelial Carcinoma Bladder+2 more
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
Started Oct 2026
1,330 enrolled
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Efficacy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer.
Started Aug 2026
200 enrolled
Prostate CancerProstateProstate Cancer Patients
A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation
Started Jul 2026
300 enrolled
KRAS G12D MutationNSCLC (Non-small Cell Lung Cancer)
Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)
Started Jun 2026
500 enrolled
Non-squamous, Non-Small Cell Lung Cancer
Worked on DOCETAXEL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.